DESCRIPTION:
Ovarian and endometrial carcinomas are among the most lethal types of tumors. However, the prognosis significantly improves with early and accurate diagnosis and prompt initiation of treatment. By simultaneously determining the levels of CA 125 and HE 4, the ROMA index (Risk of Ovarian Malignancy Algorithm) value can be determined, which assesses the risk of developing ovarian cancer – providing even greater accuracy and specificity of measurement.
DETERMINATION:
Sample: SERUM Method: immunochemistry (HE4 and CA 125) ROMA is calculated according to a formula (algorithm) from the obtained HE4 and CA125 values.
CLINICAL SIGNIFICANCE:
The tumor marker CA-125 is determined in serum and has clinical significance in the diagnosis and monitoring of ovarian cancer treatment. * Its biggest drawback in diagnosing ovarian cancer is insufficient specificity, which results in a large number of false positive results. The cause of elevated values (>35 U/mL) can be of various etiologies. Elevated CA-125 values * Physiological conditions: menstruation, pregnancy * Benign gynecological diseases: benign ovarian cysts, endometriosis, hyperstimulation syndrome, ectopic pregnancy, and ovarian fibroids * Non-gynecological diseases: peritoneal, pleural, and muscular-inflammatory disorders such as pericarditis, cirrhosis, and liver necrosis. Compared to CA125, HE4 has shown greater specificity and sensitivity, as has their combination in the form of the ROMA index calculation. Based on the ROMA index, the risk of a patient having ovarian cancer is assessed, meaning patients are categorized into low or high-risk groups for developing ovarian cancer.
RESULT:
The reference interval is indicated on each validated report, and the values depend on whether the woman is in the pre- or post-menopausal period.
45.00€